Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Hertl

Showing results (111-120 of 237) with videos related to

Pageof 24
Sort By:
Clinical Immunology (Orlando, Fla.)|April 27, 2012
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatosesLuca Fania, Giacomo Caldarola, Ralf Müller, et al.
Frontiers in Medicine|November 7, 2022
Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's diseaseDario Didona, Antonio Manuel Sequeira Santos, Tomas Cunha, et al.
Acta Dermato-Venereologica|May 30, 2007
Rowell syndrome with palmoplantar involvement and suspected epitope spreadingAlessandra Marini, Heike Draeger, Matthias Schneider, et al.
Experimental Dermatology|July 18, 2006
IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgarisRalf Müller, Vera Svoboda, Elke Wenzel, et al.
The British Journal of Dermatology|January 29, 2025
Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case seriesRoberto Maglie, Dario Didona, Farzan Solimani, et al.
Experimental Dermatology|December 15, 2015
Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgarisThomas Schmidt, Sebastian Willenborg, Thomas Hünig, et al.
Dermatology (Basel, Switzerland)|February 18, 2006
Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorptionRüdiger Eming, Jürgen Rech, Sandra Barth, et al.
Archives of Dermatology|February 21, 2007
Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)Andrea Niedermeier, Rüdiger Eming, Martin Pfütze, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 1, 2022
Lichen planus in Germany - epidemiology, treatment, and comorbidity. A retrospective claims data analysisEva Schruf, Mona Hc Biermann, Josephine Jacob, et al.
International Journal of Cancer|January 29, 2009
Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patientsCornelia Erfurt, Esther Müller, Sonja Emmerling, et al.
Pageof 24

Showing results (111-120 of 237) with videos related to

Sort By:
Pageof 24
Clinical Immunology (Orlando, Fla.)|April 27, 2012
IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatosesLuca Fania, Giacomo Caldarola, Ralf Müller, et al.
Frontiers in Medicine|November 7, 2022
Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet's diseaseDario Didona, Antonio Manuel Sequeira Santos, Tomas Cunha, et al.
Acta Dermato-Venereologica|May 30, 2007
Rowell syndrome with palmoplantar involvement and suspected epitope spreadingAlessandra Marini, Heike Draeger, Matthias Schneider, et al.
Experimental Dermatology|July 18, 2006
IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgarisRalf Müller, Vera Svoboda, Elke Wenzel, et al.
The British Journal of Dermatology|January 29, 2025
Off-label use of tralokinumab in the treatment of bullous pemphigoid: a case seriesRoberto Maglie, Dario Didona, Farzan Solimani, et al.
Experimental Dermatology|December 15, 2015
Induction of T regulatory cells by the superagonistic anti-CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA-transgenic mouse model of pemphigus vulgarisThomas Schmidt, Sebastian Willenborg, Thomas Hünig, et al.
Dermatology (Basel, Switzerland)|February 18, 2006
Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorptionRüdiger Eming, Jürgen Rech, Sandra Barth, et al.
Archives of Dermatology|February 21, 2007
Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies)Andrea Niedermeier, Rüdiger Eming, Martin Pfütze, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|August 1, 2022
Lichen planus in Germany - epidemiology, treatment, and comorbidity. A retrospective claims data analysisEva Schruf, Mona Hc Biermann, Josephine Jacob, et al.
International Journal of Cancer|January 29, 2009
Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patientsCornelia Erfurt, Esther Müller, Sonja Emmerling, et al.
Pageof 24